Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cara, S.
Right arrow Articles by Tannock, I.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cara, S.
Right arrow Articles by Tannock, I.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:23-27, 2001
© 2001 European Society for Medical Oncology

review-article

Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance

S. Cara1 and I.F. Tannock2

1Centre Leon Barred Lyon, France
2Department of Haematology and Medical Oncology, Princes Margaret Hospital Toronto, Canada

Dr I F Tannock Department of Haematology and Medical Oncology Princess Margaret Hospital 610 University Avenue Toronto, ON M5G 2M9 Canada E-mail lan.tannock{at}uhn.on.ca

BACKGROUND: Patients who relapse after adjutant chemotherapy, or after attaining remission following treatment of advanced disease, are sometimes retreated with the same type of chemotherapy The objective of the current review of published reports was to assess the probability of response to retreatment, and to examine evidence for transient rather than stable forms of clinical drug resistance

METHODS: A Medline review of published clinical series where patients were retreated with the same chemotherapy that they had received previously

RESULTS: We located 15 reports of patients with advanced disease who were retreated with the same chemotherapy following complete remission and subsequent relapse, and three reports where patients received the same chemotherapy that was given previously as adjuvant treatment for breast cancer For patients with advanced disease the median time off-treatment was 48 weeks, response rates to retreatment using appropriate criteria were in the range of 18%-100% (median 51%), with a substantial proportion of second complete responses For patients retreated after adjuvant chemotherapy for breast cancer the median interval between treatments was 84 weeks and the response rates were in the range of 40%-51%.

CONCLUSIONS: With the caveat that this type of review is subject to publication bias, retreatment of patients who relapse after complete response to initial therapy, or after adjuvant therapy, is associated with a substantial probability of response Together with evidence that more prolonged or intensive initial therapy rarely leads to more frequent or more prolonged responses, the current review suggests that some patients may develop transient resistance to chemotherapy

cancer chemotherapy, drug resistance, retreatment, review


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
F. Andre, T. Le Chevalier, and J. C. Soria
Her2-neu: a target in lung cancer?
Ann. Onc., January 1, 2004; 15(1): 3 - 4.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.